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Pregnancy and Cancer Treatment Often Are Not Mutually Exclusive
(Continued from page 1)

such women. Most of the cancers they
see are already at an advanced stage at
the time of diagnosis, in part because
both patients and physicians tend to
dismiss breast lumps during pregnancy
as changes related to the pregnancy.
“They put it down to mastitis, blocked
milk duct, some other reason,” Dr.
Theriault said. He also cites a common
fallacy that even if there is an anomaly
in the breast, nothing can be done
about it while the woman is pregnant.
Some physicians will not even do a
biopsy until after delivery, Dr. Gwyn
said, further delaying diagnosis and
treatment. Both recommend that all
pregnant women be given a thorough
clinical breast examination on their
first visit to the obstetrician, when
the women are still early in their
pregnancies and the breasts have
not yet become engorged.
The incidence of breast cancer
concurrent with pregnancy is expected
to increase as more women delay childbearing and as mammographic screening
increases. The National Cancer
Institute’s Surveillance, Epidemiology,
and End Results Program’s Cancer
Statistics Review found that women who
have their first full-term pregnancy after
age 30 have a
two to three
times higher risk
of breast cancer
than women
who have their
first pregnancy
before age 20.
Among the
women in the
M. D. Anderson
cohort, the
median age is 33,
and the oldest
woman among
the patients is
42. As a result,
Dr. Theriault
urges increased
suspicion of any
changes in the
Since 1989, more than 50 pregnant women with breast cancer have
breasts of pregbeen treated at M. D. Anderson. Dr. Richard L. Theriault, a
nant women in
professor in the Department of Breast Medical Oncology, displays
their 30s or 40s.
a photo of a healthy baby born to one of these women.

of Breast Medical Oncology and the
Department of Epidemiology, “but it is
not always necessary.” Pregnant women
can undergo biopsies and even be treated
for cancer with chemotherapy.
The cancer most commonly diagnosed during pregnancy is breast
cancer, followed by cervical cancer,
then lymphoma and thyroid cancer.
Less common are leukemia and melanoma. With the exception of most
cases of cervical cancer, pregnancy
and cancer treatment are not mutually
exclusive.
“In cervical cancer, the standard
treatment is surgery [radical hysterectomy] and radiation,” Dr. Theriault
said. “The issue is that the fetus is going
to die from the treatment, except in
unusual circumstances where the cancer
is diagnosed early through a Pap smear
and you are able to remove all the
cancerous tissue with a cervical core
biopsy and maintain the pregnancy
and delivery.”
The outlook is much better for
patients with breast cancer. Drs.
Theriault and Gwyn work with women
who have been diagnosed with breast
cancer during pregnancy. Since 1989,
their group has treated more than 50
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When an anomaly is found, Dr. Gwyn
recommends that obstetricians seek the
help of cancer specialists rather than
keep the burden of diagnosis on themselves. Accurately reading a mammogram
or an ultrasound of a pregnant woman’s
breast is difficult and requires experience,
as does interpreting the results of a biopsy
from a lactating breast.
If a pregnant woman is found to have
breast cancer, chances are it will be an
aggressive cancer. That unfortunate fact
is not related directly to the pregnancy
but rather to the age of the patients.
“The tumors occurring in pregnant
women are no different than the tumors
occurring in other young women,” said
Lavinia P. Middleton, M.D., an assistant
professor in the Department of Pathology, “but breast cancer in young women
is a histologically aggressive disease, so
it’s more the age of the patient than her
pregnancy status that affects the tumor’s
growth and prognostic markers.”
If the tumor is found early, though,
that histological aggressiveness can be
to the patient’s advantage. “Tumors that
have aggressive histological features, it
sounds like they are bad tumors, something that you don’t want to have,”
Dr. Middleton said. “But actually they
may respond better to chemotherapy
because of the rapid turnover of the
tumor cells.”
The preferred treatment for a woman
diagnosed with locally advanced or
node-positive breast cancer during
pregnancy is chemotherapy after the
first trimester, followed by surgery,
usually after childbirth. Radiation
therapy is typically not used until after
delivery in pregnant patients. The
chemotherapy administered is a standard breast cancer treatment combination of 5-fluorouracil, doxorubicin
(Adriamycin), and cyclophosphamide
(FAC). “We give it the way that we
would give it to a nonpregnant woman,
and we use the same dosages that we
would use for a nonpregnant woman,”
Dr. Gwyn said. Taxanes are not approved for use in pregnant women, so
patients with node-positive disease are
given FAC during pregnancy and a
taxane after delivery.

“Depending on the
stage of [the patient’s]
cancer and [her]
medical health,
ending the pregnancy
may be appropriate,
but it is not always
necessary.”
– Karin M.E.H. Gwyn, M.D.,
assistant professor,
Departments of Breast Medical
Oncology and Epidemiology

The fear that chemotherapy will
have adverse effects on the unborn child
has been somewhat relieved by a followup survey among the patients in the
M. D. Anderson cohort. Of the 27
children included in a survey of their
parents or guardians, all but three were
reported healthy and developing
normally. The only exceptions were one
child with Down’s syndrome, which Dr.
Gwyn said has nothing to do with
chemotherapy, and two children with
attention deficit disorder, which is not
uncommon. One question that remains
unanswered is whether the fertility of
these children will be affected, because
the oldest child from this study is only
13 years old. However, the researchers
are encouraged by the results of a study
of pregnant patients with lymphoma
who were treated with chemotherapy.
Their children have been monitored for
more than 18 years, and some of them
have already demonstrated fertility.
With the proper attention and
a high index of suspicion, more of
these aggressive breast tumors can be
caught early. “Even with those negative
prognostic attributes and characteristics,
these tumors still can be treated successfully,” Dr. Middleton said. “And the
patients can go on to lead productive
lives.” ●
FOR MORE INFORMATION, contact Dr.
Theriault or Dr. Gwyn at (713) 792-2817
or Dr. Middleton at (713) 745-0128.

Studies of the Viral Origins
of Some Cancers Lead
to New Prevention,
Treatment Strategies
by Katie Prout Matias

V

iruses are nefarious: They not only make people sick
with deadly diseases such as AIDS and smallpox but
also, by wreaking havoc on normal cellular functions,
set the machine of carcinogenesis in motion. Like other
viruses, cancer-causing viruses infiltrate cells and use their DNAsynthesizing proteins and mechanisms to replicate. If the cell-cycle
control is disrupted in the process and the infected cell grows
unchecked, the initial stages of cancer have begun.

Infectious agents contribute to up to
30% of cancer cases worldwide. The four
cancers most often caused by infection—
both bacterial and viral—are cervical
cancer, liver cancer, Kaposi’s sarcoma,
and gastric cancer. In most cases of
infection with a cancer-causing agent,
cancer does not develop; thus, infection
is only one component of a multifactorial
process that may lead to cancer.
“The goal of the virus is not to make
cancer. It is really to keep the cell alive

so the virus can propagate,” said Felipe
Samaniego, M.D., an assistant professor
in the Department of Lymphoma at The
University of Texas M. D. Anderson
Cancer Center. “The virus produces
proteins that prevent cell death, or
apoptosis, and it has multiple genes
meant to keep the cell alive. If a cell
accumulates damage and has a virus that
does not allow the cell to fix itself, the
cell has the tendency to undergo
(Continued on page 4)

Dr. Felipe Samaniego (right), an assistant professor in the Department of Lymphoma,
speaks with patient
(center) and Amira Pugh, B.S.N., a nurse in the
Lymphoma and Myeloma Center.
is part of a study in which non-Hodgkin’s
lymphoma tumors are being screened for the presence of simian virus 40 DNA sequences.
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in the Department of Gastrointestinal
Medicine and Nutrition.
Malignancy, which can take 30 to
40 years to develop, may be related to
an inflammatory process caused by
HBV. “Chronic inflammation eventually can lead to carcinoma,” said Dr.
Bresalier. “Viruses play a major role in
the development of hepatocellular
carcinoma through a long-term process
that involves chronic infection, damage
to the liver, cirrhosis, and then, eventually, cancer. That is true classically for
hepatitis B but probably also for
hepatitis C.”
A vaccine for HBV was developed
in the 1980s, but researchers have not
yet developed one for HCV, which is
becoming an epidemic, according to
Dr. Bresalier. He is nonetheless confident that a vaccine for HCV will one
day be available. In the meantime,
physicians at M. D. Anderson treat
infected patients with interferon and
antiviral medications, and Dr. Bresalier
estimates they are able to eradicate
the virus in one in three individuals,
thus halting carcinogenesis.
Lymphoma
Cells of the lymphatic system are
uniquely susceptible to viral damage;
several viruses, including simian virus 40
(SV40) DNA sequences, Epstein-Barr
virus (EBV), and human herpesvirus-8
(HHV-8), have been linked to lymphomas.

Herpesviruses, including Epstein-Barr
virus and human herpesvirus-8, may be
particularly carcinogenic because they
contain a multitude of genes that can
prevent cell death. Shown here are various
viruses from the Herpesviridae family,
as seen through an electron microscope.

“Lymphocytes are supposed to take
care of infection. By association, maybe
they are also at risk for being affected by
microbes,” said Dr. Samaniego. “Nobody
knows what comes first. Is it lymphoma
that provides a place for the virus, or is
it the other way around?”
The incidence of non-Hodgkin’s
lymphoma has increased over the past
30 years; 287,000 cases are diagnosed
each year around the world. SV40, a
monkey virus that contaminated early
versions of the polio vaccine, was given
to as many as 30 million people between
1955 and 1963. Evidence of SV40
DNA sequences has been found in
non-Hodgkin’s lymphoma and, infrequently, in other types of tumor cells.
“We don’t know what the SV40 in
the vaccine did to people. It could have
vaccinated them against the virus, or it
could have introduced it into people,”
said Dr. Samaniego. SV40 has also
appeared in people who have never
been vaccinated; it is spread from
person to person through bodily
secretions.
SV40, which like HPV works by
inactivating p53 and Rb, is also associated with brain and bone tumors,
mesotheliomas, and B-cell lymphomas.
“We think it is an old virus in humans
because whenever a new virus is
introduced into a species, it usually
causes severe illness. It kills people.
SV40 doesn’t harm people early on, but
over time it may contribute to tumor
development,” Dr. Samaniego said.
Currently, Dr. Samaniego and others
at M. D. Anderson are comparing the
prognoses of SV40-positive and SV40negative lymphomas. They are also
checking tumors resected years ago for
the presence of SV40 and testing
lymphocytes in culture to see whether
SV40 genes induce lymphoma.
Another virus associated with
lymphoma is EBV, which causes mononucleosis in young adults. EBV is spread
through saliva and may infect 80%
of people worldwide. A recent study
found that people who have contracted
mononucleosis have double the risk of
Hodgkin’s disease. However, the risk is
still low: only one in 1,000 young adults

with mononucleosis will get Hodgkin’s
disease.
EBV infects the B cells of the
immune system and produces a protein
called LMP1 that mimics CD40, an
important immune cell molecule. This
allows the virus to manipulate immune
cell regulation pathways for its own
designs. EBV, which has been linked to
invasive breast cancer, can also disable a
cellular protein that normally suppresses
malignant cell migration, thus allowing
cancerous cells to metastasize.
Strangely, EBV infection is associated with distinct cancers in different
regions of the world. In North America
and Europe, EBV infection is linked to
Hodgkin’s disease, whereas in China
it is linked to nasopharyngeal cancer
and in Africa to Burkitt’s lymphoma.
Nearly all cases of Burkitt’s lymphoma
in Africa have evidence of EBV infection, compared with only 15% to 20%
of cases in the United States. Environmental factors may play a large part in
these unique manifestations.
EBV is one of many cancer-causing
viruses that belong to the human
herpesvirus family, the members of
which also cause cold sores, genital
herpes, and chicken pox. According to
Dr. Samaniego, herpesviruses may be
particularly carcinogenic because they
contain a multitude of genes that can
prevent apoptosis.
Another member of the herpesvirus
family associated with lymphoma is
HHV-8. Recently isolated, HHV-8
contains many human oncogene homologues, including cyclin D and bcl-2.
One hundred percent of cases of primary
effusion lymphoma and Kaposi’s sarcoma
contain HHV-8.
HIV and cancer:
a symbiotic relationship
People infected with human immunodeficiency virus-1 (HIV-1) have an
enormously increased risk of cancer,
especially Kaposi’s sarcoma and lymphoma. “With HIV infection, we
have had a surge of new cancers,” Dr.
Samaniego said. “We have 40 million
people worldwide infected by HIV, and
(Continued on page 6)
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Studies of Viral Origins of Cancer
(Continued from page 5)

about two million have some kind of
cancer associated with HIV infection.”
According to Dr. Samaniego, HIV-1
causes cancer indirectly and through
more than one mechanism. One
pathway to cancer involves the HIV-1
Tat protein, which allows HIV to
replicate itself many times over. HIV-1
Tat is known to activate several genes
that make cells prone to cancer. In
one study at M. D. Anderson, Dr.
Samaniego introduced Kaposi’s sarcoma
cells into transgenic mice expressing
HIV-1 Tat. The mice with Tat expressed
higher levels of inflammatory and
growth-promoting cytokines and
grew bigger tumors than did the control
mice.
Additionally, HIV-1 appears to travel
with and enable other oncogenic viruses
such as HHV-8. Dr. Samaniego and
others at M. D. Anderson have conducted several studies of the relationship among HHV-8, HIV-1, and
Kaposi’s sarcoma. They found that K1,
a gene in HHV-8, interacts with HIV-1
Tat to promote inflammation, which
may play an important role in advancing Kaposi’s sarcoma. “What you find is
that HIV-1 infection allows other viral
infections to spread, and most of these
viruses are associated with cancer,” said
Dr. Samaniego.
Gastrointestinal cancers
After years of dispute, scientists now
agree that Helicobacter pylori—a bacterium, rather than a virus, that causes
90% of duodenal ulcers—also causes
40% to 60% of all gastric cancers. This
finding has prompted researchers to take
a closer look at other infectious agents
that may contribute to cancers of the
gastrointestinal tract.
Two likely suspects are the human
cytomegalovirus and the JC virus. The
human cytomegalovirus, a typically
asymptomatic herpesvirus that is
transmitted through bodily fluids and
infects 40% of the population in the
United States, has been found in 85%
of colon cancer cells. It has also been
found in brain tumors. The JC virus, a
polyomavirus found in 80% of adults,
has been found in 89% of colon cancers.
6
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Viruses and Associated Human Cancers
Cofactors

Virus

Type of Cancer

Epstein-Barr virus (EBV)

Burkitt’s lymphoma
Nasopharyngeal carcinoma
B-cell lymphoma
Hodgkin’s disease
Breast cancer (suspected)

➞
➞
➞
➞
➞

Hepatitis B virus (HBV)

Liver cancer

➞ Aflatoxin, alcohol

Hepatitis C virus (HCV)

Splenic lymphoma
Liver cancer

➞ Unknown
➞ Aflatoxin, alcohol

Human herpesvirus-8
(HHV-8)

Kaposi’s sarcoma
➞ HIV-1
Primary effusion lymphoma ➞ EBV and HIV-1
Multicentric Castleman
➞ HIV-1
disease

Human papillomavirus
(HPV)

Cervical, vulvar, vaginal,
penile, anal, skin,
oropharyngeal

➞ Smoking, oral contraceptives, multiparity, other
sexually transmitted
diseases

Human T-cell
lymphotropic virus type 1
(HTLV-1)

Adult T-cell leukemia/
lymphoma (ATL)

➞ Unknown

Simian virus 40 (SV40)

Mesothelioma
➞ Asbestos
Non-Hodgkin’s lymphoma, ➞ Unknown
brain and bone tumors,
and B-cell lymphomas
(suspected)

Also asymptomatic, the JC virus is
believed to infect people through
the oral-fecal route.
Viral treatments
The good news about the role that
viruses play in carcinogenesis is that
vaccines now hold great promise in
preventing and treating cancer. Indeed,
vaccines against HPV and HBV may
decrease the global cancer incidence by
15%; the vaccine for HBV has already
had a major impact on the rates of
hepatocellular carcinoma. Researchers
also are working to develop vaccines for
HIV-1 and EBV, as well as for HCV.
Furthermore, viruses may also be
used to deliver gene therapy to patients
with cancer and other illnesses. At
M. D. Anderson, Dr. Bresalier and his
colleagues are studying the use of viruses

Malaria
Nitrosamines
Immunodeficiency, HIV-1
Unknown
Unknown

as vectors to deliver tumor necrosis
factor directly to esophageal adenocarcinomas. “The idea is that this will spread
the agent within the tumor and cause
either necrosis of the tumor or sensitize
the tumor to radiation treatment,” said
Dr. Bresalier.
“I think the wave of the future is how
viruses can be supportive in therapy,”
said Dr. Samaniego. “We are looking for
effective ways of preventing lymphoma
and other cancers, so I think a lot of
what you will see in the next few years
is going to be [using viruses as therapy].
It is going to be a low-cost modality that
is applicable worldwide.” ●
FOR MORE INFORMATION, contact
Dr. Samaniego at (713) 792-2860,
Dr. Tortolero-Luna at (713) 745-2352,
or Dr. Bresalier at (713) 745-4340.

